|
A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia Clinical research trials and A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia. A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia clinical trial. Human subjects frequently get the finest healthcare available for their A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia
A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia
For Condition: Renal Anemia
Status: No longer recruiting
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The purpose of this study is to evaluate switching from i.v. epoetin alfa to Ro 50-3821 in hemodialysis patients with chronic renal anemia. How often Ro 50-3821 needs to be administered to provide a stable hemoglobin levels after switching from epoetin alfa will also be evaluated.
Details:
Eligibility:
Study Type: Interventional,燭reatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Adult patients (at least 18 years old) with chronic renal anemia - Hemodialysis therapy at least three times weekly for at least 3 months - On epoetin alfa maintenance treatment for the last 3 months - Body weight of at least 60 kg Exclusion Criteria: - Conditions known to effect your response to epoetin or anemia not related to chronic renal failure, examples below, but exclusion not limited to: 路 Any acute infections 路 Rheumatoid arthritis or Systemic lupus 路 Stomach problems 路 Thyroid disease 路 Blood disorders such as sickle cell disease of thalassemia of all types 路 Most cancers - Blood transfusions within the 3 months prior to screening - High blood pressure, stroke, heart disease, liver disease - Epilepsy - Life expectancy below 6 months - Pregnancy or breast-feeding
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: BA16285;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048035
Other Renal Anemia Studies:
1. A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered subcutaneously for the maintenance treatment of anemia in patients w/ chronic kidney disease who are on dialysis
2. A randomized, controlled, open-label, multicenter, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis
3. A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients w/ chronic kidney disease who are on dialysis
4. A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia
5. An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis
Related Studies:
Other Renal Anemia Clinical Trials
Other Kentucky Clinical Trials
Other Louisville Clinical Trials
A study of switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Ro 50-3821 in hemodialysis patients with chronic renal anemia
|
|
|
|
|
|
|
|